L'Institut Paoli - Calmettes
Welcome,         Profile    Billing    Logout  
 15 Trials 
33 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
DAYEN, Charles
DIAL, NCT05255302 / 2021-006044-27: De-escalation Immunotherapy mAintenance Duration Trial for Stage IV Lung Cancer Patients With Disease Control After Chemo-immunotherapy Induction

Recruiting
2/3
1360
Europe
Pembrolizumab before randomization, Chemotherapy, Pemetrexed, Pembrolizumab after randomization
Intergroupe Francophone de Cancerologie Thoracique, IFCT
Metastatic NSCLC
05/25
06/29
ORAKLE, NCT04111705: Lorlatinib After Failure of First-line Second-generation ALK Kinase Inhibitor in Patients With Advanced ALK-positive Non-small Cell Lung Cancer

Completed
2
23
Europe
Lorlatinib
Intergroupe Francophone de Cancerologie Thoracique
Non Small Cell Lung Cancer Metastatic
08/22
12/24
ENCO-BRAF, NCT04526782 / 2019-004621-24: ENCOrafenib With Binimetinib in bRAF NSCLC

Hourglass Jul 2022 - Dec 2022 : Pivotal data readout from ENCO-BRAF trial in combination with Mektovi for NSCLC
Active, not recruiting
2
119
Europe
Encorafenib 75 MG, Binimetinib 15 MG
Intergroupe Francophone de Cancerologie Thoracique, IFCT, Pierre Fabre
Non Small Cell Lung Cancer, BRAF V600E
06/25
03/26
IFCT-2101 MASTERPROTOCOL ALK, NCT05200481: Study of Safety and Efficacy of Brigatinib Plus Chemotherapy or Brigatinib Only in Advanced ALK-Positive Lung Cancer (MASTERPROTOCOL ALK)

Active, not recruiting
2
110
Europe
Brigatinib 180 MG, ALUNBRIG, Carboplatin, Pemetrexed
Intergroupe Francophone de Cancerologie Thoracique
Non Small Cell Lung Cancer, ALK Gene Mutation
04/25
10/28
TAXIO, NCT05856695: Durvalumab Plus Etoposide-free Chemotherapy in First-line Treatment of Extensive-disease Small-sell Lung Cancer (SCLC)

Recruiting
2
67
Europe
Carboplatin + Paclitaxel + Durvalumab
Intergroupe Francophone de Cancerologie Thoracique
Small Cell Lung Cancer Extensive Stage
02/26
02/28
METex14, NCT04868877 / 2021-000203-20: Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination

Recruiting
1/2
576
Europe, US, RoW
MCLA-129, bispecific, Osimertinib, Tagrisso, Chemotherapy
Merus N.V.
Non-Small Cell Lung Cancer Metastatic, Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer
03/26
03/27
EXTRACT, NCT05207423: A Chart Review Study of Adults With Advanced NSCLC

Completed
N/A
179
Europe, Canada, RoW
Takeda
Non-small Cell Lung Cancer (NSCLC)
02/23
02/23
Ibe2i-TIPCI, NCT05813418: Identification of Predictive Biomarkers for Immune-Related Adverse Events (irAEs) in Patients Undergoing Immune CheckPoint Inhibitors (ICPI) Treatment

Recruiting
N/A
150
Europe
blood retriewal
Centre Hospitalier Universitaire, Amiens, Central Hospital Saint Quentin
Immunotherapy, Immune Checkpoint Inhibitors, Immune-related Adverse Event, Predictive Biomarkers
12/25
12/25
Duruisseaux, Michael
SUNRAY-02, NCT06890598: Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

Recruiting
3
700
Europe, Japan, US, RoW
Olomorasib, LY3537982, Pembrolizumab, Durvalumab, Placebo
Eli Lilly and Company, AstraZeneca
Carcinoma, Non-Small-Cell Lung
05/29
02/32
SUNRAY-01, NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Recruiting
3
1016
Europe, Canada, Japan, US, RoW
LY3537982, Olomorasib, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed
Eli Lilly and Company, Loxo Oncology, Inc.
Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
10/26
10/29
LIBRETTO-432, NCT04819100 / 2020-005191-35: A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)

Active, not recruiting
3
152
Europe, Canada, Japan, US, RoW
Selpercatinib, LY3527723, LOXO-292, Placebo
Eli Lilly and Company, Loxo Oncology, Inc.
Carcinoma, Non-Small-Cell Lung
05/26
05/28
eNRGy, NCT02912949 / 2014-003277-42: A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion

Active, not recruiting
2
250
Europe, Canada, Japan, US, RoW
zenocutuzumab (MCLA-128), bispecific, MCLA-128
Partner Therapeutics, Inc.
Solid Tumours Harboring NRG1 Fusion, NSCLC Harboring NRG1 Fusion, Pancreatic Cancer Harboring NRG1 Fusion, NRG1 Fusion
12/26
12/26
SAVIMMUNE, NCT04108026 / 2018-004742-42: Immunotherapy in Patient with Poor General Condition

Active, not recruiting
2
50
Europe
Durvalumab
Intergroupe Francophone de Cancerologie Thoracique, IFCT, AstraZeneca
Non-small Cell Lung Cancer Stage IV
11/23
10/25
NIVOTHYM, NCT03134118 / 2015-005504-28: Nivolumab in Patients With Type B3 Thymoma and Thymic Carcinoma

Active, not recruiting
2
55
Europe
Nivolumab, BMS-936558-01
European Organisation for Research and Treatment of Cancer - EORTC, ETOP IBCSG Partners Foundation
Thymoma Type B3, Thymic Carcinoma
12/23
07/24
ORAKLE, NCT04111705: Lorlatinib After Failure of First-line Second-generation ALK Kinase Inhibitor in Patients With Advanced ALK-positive Non-small Cell Lung Cancer

Completed
2
23
Europe
Lorlatinib
Intergroupe Francophone de Cancerologie Thoracique
Non Small Cell Lung Cancer Metastatic
08/22
12/24
NCT04621188: Lorlatinib After Failure of First-line TKI in Patients with Advanced ROS1-positive NSCLC (ALBATROS)

Active, not recruiting
2
54
Europe
Lorlatinib
Intergroupe Francophone de Cancerologie Thoracique
Non Small Cell Lung Cancer Metastatic
02/25
02/27
IFCT-2101 MASTERPROTOCOL ALK, NCT05200481: Study of Safety and Efficacy of Brigatinib Plus Chemotherapy or Brigatinib Only in Advanced ALK-Positive Lung Cancer (MASTERPROTOCOL ALK)

Active, not recruiting
2
110
Europe
Brigatinib 180 MG, ALUNBRIG, Carboplatin, Pemetrexed
Intergroupe Francophone de Cancerologie Thoracique
Non Small Cell Lung Cancer, ALK Gene Mutation
04/25
10/28
METex14, NCT04868877 / 2021-000203-20: Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination

Recruiting
1/2
576
Europe, US, RoW
MCLA-129, bispecific, Osimertinib, Tagrisso, Chemotherapy
Merus N.V.
Non-Small Cell Lung Cancer Metastatic, Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer
03/26
03/27
EXTRACT, NCT05207423: A Chart Review Study of Adults With Advanced NSCLC

Completed
N/A
179
Europe, Canada, RoW
Takeda
Non-small Cell Lung Cancer (NSCLC)
02/23
02/23
CANUT-2, NCT05027490: CAncer, NUtrition and Taste 2

Completed
N/A
209
Europe
CANUT support, Anthropometric measures, Prehension strength measurement, QVA Questionnaire, QLQ C30 Questionnaire, Scratch & Snif Test, Taste Strip Test, 24 H feed back questionnaire, Condiment questionnaire, Tobacco questionnaire, Nutrition interview
Hospices Civils de Lyon
Breast Cancer, Gynecologic Cancer, Bronchial Cancer, Breast, Gynecological or Bronchial Cancer Treated With Intravenous Chemotherapy
09/23
09/23
ODYSSEE, NCT06131775: Characterisation of TLR4+ Blood Cells in Patients With Solid Cancer

Recruiting
N/A
300
Europe
Blood sampling
Hospices Civils de Lyon
All Types of Solid Cancer
05/28
05/28
ILYAD, NCT05452200: Lung Cancer Screening Implementation Among Employees at Lyon Hospital

Recruiting
N/A
600
Europe
Solicitation for lung cancer screening, added exams to the usual lung cancer screening
Hospices Civils de Lyon
Lung Cancer
09/24
09/24
DRACONIS, NCT06781905: Description of Neurocognitive and Psychiatric Disorders Associated with Targeted Therapies Used in the Treatment of Lung Cancers with ALK/ROS1 Fusion and Their Impact on Patients' Quality of Life: Construction of an Experimental Patient-researcher Collaborative Care and Research Pathway

Not yet recruiting
N/A
20
Europe
Assessments of neuropsychiatric, neurocognitive and psychosocial alterations
Hospices Civils de Lyon
Metastatic Lung Cancer, Metastatic Lung Cancer with ALK/ROS1 Fusion
05/27
05/27
ONCOPRO, NCT03787056: Predictive Value of Progastrin Titer at Diagnosis and of Progastrin Kinetics During Treatment in Cancer Patients

Recruiting
N/A
410
Europe
Blood draws
Hospices Civils de Lyon
Cancer, Breast Cancer, Gastric Cancer, Renal Cancer, Prostate Cancer, Melanoma, Lung Cancer, Hepatocellular Cancer, Colorectal Cancer, Head and Neck Cancer, Pancreatic Cancer, Ovarian Cancer, Glioblastoma, Endometrial Cancer, Bladder Cancer, Esophageal Cancer, B-cell Lymphoma
01/28
01/28
MONITOR, NCT04605146: Impact of Telemonitoring for the Management of Side Effects in Patients with Melanoma, Lung or Renal Cancer, Treated with Immunotherapy Combination of Nivolumab and Ipilimumab or Adjuvant Nivolumab Monotherapy

Recruiting
N/A
100
Europe
Tele-monitoring
Hospices Civils de Lyon
Melanoma, Lung Cancer, Renal Cancer
11/28
11/28
IMMUCARE-BASE, NCT03989323: A Clinical and Biological Prospective Database of Patients Treated With Anticancer Immunotherapy and Follow up of Their Immune-related Adverse Events irAE

Recruiting
N/A
2000
Europe
Estimation of the incidence of the irAE
Hospices Civils de Lyon
Cancer
07/29
07/29
Stoppa, Anne-Marie
DREAMM8, NCT04484623 / 2018-004354-21: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma

Jan 2024 - Dec 2024: Market entry for 2L multiple myeloma (based on DREAMM-7 trial)
Hourglass Oct 2024 - Dec 2024 : Acceptance of regulatory submission in US for 2L+ multiple myeloma
Hourglass Jul 2024 - Dec 2024 : Acceptance of regulatory submission in EU for 2L+ multiple myeloma (based on DREAMM-8 trial)
Jan 2024 - Dec 2024: Regulatory approval in US for 2L+ multiple myeloma (based on DREAMM-7 trial)
Jan 2024 - Dec 2024: Regulatory approval in EU for 2L+ multiple myeloma (based on DREAMM-7 trial)
More
Active, not recruiting
3
302
Europe, Japan, US, RoW
Belantamab mafodotin, Pomalidomide, Dexamethasone, Bortezomib
GlaxoSmithKline
Multiple Myeloma
01/24
10/29
IFM2018-01, NCT03669445: Study Association of Lenalidomide, Ixazomib, Dexamethasone and Daratumumab in Newly Diagnosed Standard Risk Multiple Myeloma

Recruiting
2
45
Europe
Ixazomib, Lenalidomide, Dexamethasone, Daratumumab
University Hospital, Toulouse
Multiple Myeloma
03/24
12/24
NCT03309111: Study of ISB 1342, a CD38/CD3 Bispecific Antibody, in Subjects With Previously Treated Multiple Myeloma

Completed
1
81
Europe, US
ISB 1342
Ichnos Sciences SA, Glenmark Pharmaceuticals S.A.
Relapsed/Refractory Multiple Myeloma
12/23
12/23
Vicier, Cecile
METex14, NCT04868877 / 2021-000203-20: Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination

Recruiting
1/2
576
Europe, US, RoW
MCLA-129, bispecific, Osimertinib, Tagrisso, Chemotherapy
Merus N.V.
Non-Small Cell Lung Cancer Metastatic, Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer
03/26
03/27
DF1001-001, NCT04143711 / 2019-004706-10: Study of DF1001 in Patients with Advanced Solid Tumors

Recruiting
1/2
378
Europe, US, RoW
DF1001, Nivolumab, Nab paclitaxel, Sacituzumab Govitecan-hziy
Dragonfly Therapeutics, Dragonfly Therapeutics, Inc.
Solid Tumor, Adult
10/26
12/26
NCT04586270: A Study of TAS0612 in Participants With Advanced or Metastatic Solid Tumor Cancer

Terminated
1
47
Europe, US
TAS0612
Taiho Oncology, Inc.
Advanced or Metastatic Solid Tumors
11/24
11/24
KEYNOTE-G13, NCT06108479: Study of DF6215 in Patients with Advanced Solid Tumors

Recruiting
1
255
Europe, US, RoW
DF6215, pembrolizumab, KEYTRUDA®
Dragonfly Therapeutics, Merck Sharp & Dohme LLC
Solid Tumor, Adult, Solid Tumor Cancer
03/26
12/27
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
DAYEN, Charles
DIAL, NCT05255302 / 2021-006044-27: De-escalation Immunotherapy mAintenance Duration Trial for Stage IV Lung Cancer Patients With Disease Control After Chemo-immunotherapy Induction

Recruiting
2/3
1360
Europe
Pembrolizumab before randomization, Chemotherapy, Pemetrexed, Pembrolizumab after randomization
Intergroupe Francophone de Cancerologie Thoracique, IFCT
Metastatic NSCLC
05/25
06/29
ORAKLE, NCT04111705: Lorlatinib After Failure of First-line Second-generation ALK Kinase Inhibitor in Patients With Advanced ALK-positive Non-small Cell Lung Cancer

Completed
2
23
Europe
Lorlatinib
Intergroupe Francophone de Cancerologie Thoracique
Non Small Cell Lung Cancer Metastatic
08/22
12/24
ENCO-BRAF, NCT04526782 / 2019-004621-24: ENCOrafenib With Binimetinib in bRAF NSCLC

Hourglass Jul 2022 - Dec 2022 : Pivotal data readout from ENCO-BRAF trial in combination with Mektovi for NSCLC
Active, not recruiting
2
119
Europe
Encorafenib 75 MG, Binimetinib 15 MG
Intergroupe Francophone de Cancerologie Thoracique, IFCT, Pierre Fabre
Non Small Cell Lung Cancer, BRAF V600E
06/25
03/26
IFCT-2101 MASTERPROTOCOL ALK, NCT05200481: Study of Safety and Efficacy of Brigatinib Plus Chemotherapy or Brigatinib Only in Advanced ALK-Positive Lung Cancer (MASTERPROTOCOL ALK)

Active, not recruiting
2
110
Europe
Brigatinib 180 MG, ALUNBRIG, Carboplatin, Pemetrexed
Intergroupe Francophone de Cancerologie Thoracique
Non Small Cell Lung Cancer, ALK Gene Mutation
04/25
10/28
TAXIO, NCT05856695: Durvalumab Plus Etoposide-free Chemotherapy in First-line Treatment of Extensive-disease Small-sell Lung Cancer (SCLC)

Recruiting
2
67
Europe
Carboplatin + Paclitaxel + Durvalumab
Intergroupe Francophone de Cancerologie Thoracique
Small Cell Lung Cancer Extensive Stage
02/26
02/28
METex14, NCT04868877 / 2021-000203-20: Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination

Recruiting
1/2
576
Europe, US, RoW
MCLA-129, bispecific, Osimertinib, Tagrisso, Chemotherapy
Merus N.V.
Non-Small Cell Lung Cancer Metastatic, Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer
03/26
03/27
EXTRACT, NCT05207423: A Chart Review Study of Adults With Advanced NSCLC

Completed
N/A
179
Europe, Canada, RoW
Takeda
Non-small Cell Lung Cancer (NSCLC)
02/23
02/23
Ibe2i-TIPCI, NCT05813418: Identification of Predictive Biomarkers for Immune-Related Adverse Events (irAEs) in Patients Undergoing Immune CheckPoint Inhibitors (ICPI) Treatment

Recruiting
N/A
150
Europe
blood retriewal
Centre Hospitalier Universitaire, Amiens, Central Hospital Saint Quentin
Immunotherapy, Immune Checkpoint Inhibitors, Immune-related Adverse Event, Predictive Biomarkers
12/25
12/25
Duruisseaux, Michael
SUNRAY-02, NCT06890598: Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

Recruiting
3
700
Europe, Japan, US, RoW
Olomorasib, LY3537982, Pembrolizumab, Durvalumab, Placebo
Eli Lilly and Company, AstraZeneca
Carcinoma, Non-Small-Cell Lung
05/29
02/32
SUNRAY-01, NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Recruiting
3
1016
Europe, Canada, Japan, US, RoW
LY3537982, Olomorasib, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed
Eli Lilly and Company, Loxo Oncology, Inc.
Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
10/26
10/29
LIBRETTO-432, NCT04819100 / 2020-005191-35: A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)

Active, not recruiting
3
152
Europe, Canada, Japan, US, RoW
Selpercatinib, LY3527723, LOXO-292, Placebo
Eli Lilly and Company, Loxo Oncology, Inc.
Carcinoma, Non-Small-Cell Lung
05/26
05/28
eNRGy, NCT02912949 / 2014-003277-42: A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion

Active, not recruiting
2
250
Europe, Canada, Japan, US, RoW
zenocutuzumab (MCLA-128), bispecific, MCLA-128
Partner Therapeutics, Inc.
Solid Tumours Harboring NRG1 Fusion, NSCLC Harboring NRG1 Fusion, Pancreatic Cancer Harboring NRG1 Fusion, NRG1 Fusion
12/26
12/26
SAVIMMUNE, NCT04108026 / 2018-004742-42: Immunotherapy in Patient with Poor General Condition

Active, not recruiting
2
50
Europe
Durvalumab
Intergroupe Francophone de Cancerologie Thoracique, IFCT, AstraZeneca
Non-small Cell Lung Cancer Stage IV
11/23
10/25
NIVOTHYM, NCT03134118 / 2015-005504-28: Nivolumab in Patients With Type B3 Thymoma and Thymic Carcinoma

Active, not recruiting
2
55
Europe
Nivolumab, BMS-936558-01
European Organisation for Research and Treatment of Cancer - EORTC, ETOP IBCSG Partners Foundation
Thymoma Type B3, Thymic Carcinoma
12/23
07/24
ORAKLE, NCT04111705: Lorlatinib After Failure of First-line Second-generation ALK Kinase Inhibitor in Patients With Advanced ALK-positive Non-small Cell Lung Cancer

Completed
2
23
Europe
Lorlatinib
Intergroupe Francophone de Cancerologie Thoracique
Non Small Cell Lung Cancer Metastatic
08/22
12/24
NCT04621188: Lorlatinib After Failure of First-line TKI in Patients with Advanced ROS1-positive NSCLC (ALBATROS)

Active, not recruiting
2
54
Europe
Lorlatinib
Intergroupe Francophone de Cancerologie Thoracique
Non Small Cell Lung Cancer Metastatic
02/25
02/27
IFCT-2101 MASTERPROTOCOL ALK, NCT05200481: Study of Safety and Efficacy of Brigatinib Plus Chemotherapy or Brigatinib Only in Advanced ALK-Positive Lung Cancer (MASTERPROTOCOL ALK)

Active, not recruiting
2
110
Europe
Brigatinib 180 MG, ALUNBRIG, Carboplatin, Pemetrexed
Intergroupe Francophone de Cancerologie Thoracique
Non Small Cell Lung Cancer, ALK Gene Mutation
04/25
10/28
METex14, NCT04868877 / 2021-000203-20: Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination

Recruiting
1/2
576
Europe, US, RoW
MCLA-129, bispecific, Osimertinib, Tagrisso, Chemotherapy
Merus N.V.
Non-Small Cell Lung Cancer Metastatic, Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer
03/26
03/27
EXTRACT, NCT05207423: A Chart Review Study of Adults With Advanced NSCLC

Completed
N/A
179
Europe, Canada, RoW
Takeda
Non-small Cell Lung Cancer (NSCLC)
02/23
02/23
CANUT-2, NCT05027490: CAncer, NUtrition and Taste 2

Completed
N/A
209
Europe
CANUT support, Anthropometric measures, Prehension strength measurement, QVA Questionnaire, QLQ C30 Questionnaire, Scratch & Snif Test, Taste Strip Test, 24 H feed back questionnaire, Condiment questionnaire, Tobacco questionnaire, Nutrition interview
Hospices Civils de Lyon
Breast Cancer, Gynecologic Cancer, Bronchial Cancer, Breast, Gynecological or Bronchial Cancer Treated With Intravenous Chemotherapy
09/23
09/23
ODYSSEE, NCT06131775: Characterisation of TLR4+ Blood Cells in Patients With Solid Cancer

Recruiting
N/A
300
Europe
Blood sampling
Hospices Civils de Lyon
All Types of Solid Cancer
05/28
05/28
ILYAD, NCT05452200: Lung Cancer Screening Implementation Among Employees at Lyon Hospital

Recruiting
N/A
600
Europe
Solicitation for lung cancer screening, added exams to the usual lung cancer screening
Hospices Civils de Lyon
Lung Cancer
09/24
09/24
DRACONIS, NCT06781905: Description of Neurocognitive and Psychiatric Disorders Associated with Targeted Therapies Used in the Treatment of Lung Cancers with ALK/ROS1 Fusion and Their Impact on Patients' Quality of Life: Construction of an Experimental Patient-researcher Collaborative Care and Research Pathway

Not yet recruiting
N/A
20
Europe
Assessments of neuropsychiatric, neurocognitive and psychosocial alterations
Hospices Civils de Lyon
Metastatic Lung Cancer, Metastatic Lung Cancer with ALK/ROS1 Fusion
05/27
05/27
ONCOPRO, NCT03787056: Predictive Value of Progastrin Titer at Diagnosis and of Progastrin Kinetics During Treatment in Cancer Patients

Recruiting
N/A
410
Europe
Blood draws
Hospices Civils de Lyon
Cancer, Breast Cancer, Gastric Cancer, Renal Cancer, Prostate Cancer, Melanoma, Lung Cancer, Hepatocellular Cancer, Colorectal Cancer, Head and Neck Cancer, Pancreatic Cancer, Ovarian Cancer, Glioblastoma, Endometrial Cancer, Bladder Cancer, Esophageal Cancer, B-cell Lymphoma
01/28
01/28
MONITOR, NCT04605146: Impact of Telemonitoring for the Management of Side Effects in Patients with Melanoma, Lung or Renal Cancer, Treated with Immunotherapy Combination of Nivolumab and Ipilimumab or Adjuvant Nivolumab Monotherapy

Recruiting
N/A
100
Europe
Tele-monitoring
Hospices Civils de Lyon
Melanoma, Lung Cancer, Renal Cancer
11/28
11/28
IMMUCARE-BASE, NCT03989323: A Clinical and Biological Prospective Database of Patients Treated With Anticancer Immunotherapy and Follow up of Their Immune-related Adverse Events irAE

Recruiting
N/A
2000
Europe
Estimation of the incidence of the irAE
Hospices Civils de Lyon
Cancer
07/29
07/29
Stoppa, Anne-Marie
DREAMM8, NCT04484623 / 2018-004354-21: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma

Jan 2024 - Dec 2024: Market entry for 2L multiple myeloma (based on DREAMM-7 trial)
Hourglass Oct 2024 - Dec 2024 : Acceptance of regulatory submission in US for 2L+ multiple myeloma
Hourglass Jul 2024 - Dec 2024 : Acceptance of regulatory submission in EU for 2L+ multiple myeloma (based on DREAMM-8 trial)
Jan 2024 - Dec 2024: Regulatory approval in US for 2L+ multiple myeloma (based on DREAMM-7 trial)
Jan 2024 - Dec 2024: Regulatory approval in EU for 2L+ multiple myeloma (based on DREAMM-7 trial)
More
Active, not recruiting
3
302
Europe, Japan, US, RoW
Belantamab mafodotin, Pomalidomide, Dexamethasone, Bortezomib
GlaxoSmithKline
Multiple Myeloma
01/24
10/29
IFM2018-01, NCT03669445: Study Association of Lenalidomide, Ixazomib, Dexamethasone and Daratumumab in Newly Diagnosed Standard Risk Multiple Myeloma

Recruiting
2
45
Europe
Ixazomib, Lenalidomide, Dexamethasone, Daratumumab
University Hospital, Toulouse
Multiple Myeloma
03/24
12/24
NCT03309111: Study of ISB 1342, a CD38/CD3 Bispecific Antibody, in Subjects With Previously Treated Multiple Myeloma

Completed
1
81
Europe, US
ISB 1342
Ichnos Sciences SA, Glenmark Pharmaceuticals S.A.
Relapsed/Refractory Multiple Myeloma
12/23
12/23
Vicier, Cecile
METex14, NCT04868877 / 2021-000203-20: Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination

Recruiting
1/2
576
Europe, US, RoW
MCLA-129, bispecific, Osimertinib, Tagrisso, Chemotherapy
Merus N.V.
Non-Small Cell Lung Cancer Metastatic, Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer
03/26
03/27
DF1001-001, NCT04143711 / 2019-004706-10: Study of DF1001 in Patients with Advanced Solid Tumors

Recruiting
1/2
378
Europe, US, RoW
DF1001, Nivolumab, Nab paclitaxel, Sacituzumab Govitecan-hziy
Dragonfly Therapeutics, Dragonfly Therapeutics, Inc.
Solid Tumor, Adult
10/26
12/26
NCT04586270: A Study of TAS0612 in Participants With Advanced or Metastatic Solid Tumor Cancer

Terminated
1
47
Europe, US
TAS0612
Taiho Oncology, Inc.
Advanced or Metastatic Solid Tumors
11/24
11/24
KEYNOTE-G13, NCT06108479: Study of DF6215 in Patients with Advanced Solid Tumors

Recruiting
1
255
Europe, US, RoW
DF6215, pembrolizumab, KEYTRUDA®
Dragonfly Therapeutics, Merck Sharp & Dohme LLC
Solid Tumor, Adult, Solid Tumor Cancer
03/26
12/27

Download Options